[1]
|
中国抗癌协会乳腺癌专业委员会. 中国乳腺癌筛查与早期诊断指南[J]. 中国癌症杂志, 2022, 32(4): 363-372.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Lin, S., Jiang, X., Zhang, G., Xiao, X., Ma, X., Wu, J., Qiu, D., Li, X., Yan, X. and Ma, M. (2022) The Chinese Herbal Formula Ruyan Neixiao Cream Inhibits An-giogenesis of Precancerous Breast Lesions via Regulation of Ras/Raf/MEK/ERK Signaling Pathway. Integrative Cancer Therapies, 21.
https://doi.org/10.1177/15347354211069397
|
[4]
|
Lakhani, S.R. (1999) The Transition from Hyperplasia to Inva-sive Carcinoma of the Breast. The Journal of Pathology, 187, 272-278. https://doi.org/10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2
|
[5]
|
Tan, P.H., Ellis, I., Allison, K., Brogi, E., Fox, S.B., Lakhani, S., Lazar, A.J., Morris, E.A., Sahin, A., Salgado, R., Sapino, A., Sasano, H., Schnitt, S., Sotiriou, C., Van Diest, P., White, V.A., Lokuhetty, D. and Cree, I.A. (2020) The 2019 World Health Or-ganization Classification of Tumours of the Breast. Histopathology, 77, 181-185.
https://doi.org/10.1111/his.14091
|
[6]
|
Li, D., Fan, H., Dong, J., Sun, C., Su, Y., Liu, J. and Gu, Y. (2021) Based on BATMAN-TCM to Explore the Molecular Mechanism of Xihuang Pill Regulating Immune Function to Treat Breast Precancerous Lesions. Breast Cancer, 13, 725-742. https://doi.org/10.2147/BCTT.S339607
|
[7]
|
中华人民共和国国家卫生健康委员会. 乳腺癌诊疗指南(2022年版) [J]. 中国合理用药探索, 2022, 19(10): 1-26.
|
[8]
|
滕熠, 曹毛毛, 陈万青. 中国癌症筛查的发展、现状与挑战[J]. 中国肿瘤, 2022, 31(7): 481-487.
|
[9]
|
Rintala, S., Dahlstrom, K.R., Franco, E.L. and Louvanto, K. (2023) A Synthesis of Evidence for Cancer-Specific Screening Interventions: A Preventive Medicine Golden Jubilee Review. Preventive Medicine, 167, Article ID: 107395.
https://doi.org/10.1016/j.ypmed.2022.107395
|
[10]
|
Pöschke, P., Wenkel, E., Hack, C.C., Beckmann, M.W., Uder, M. and Ohlmeyer, S. (2023) Low-Risk Women with Suspicious Microcalcifications in Mammography-Can an Addition-al Breast MRI Reduce the Biopsy Rate? Diagnostics, 13, Article 1197. https://doi.org/10.3390/diagnostics13061197
|
[11]
|
Miller, K.N., Thomas, S.M., Sergesketter, A.R., Rosenberger, L.H., Dilalla, G., van den Bruele, A.B., Hwang, E.S. and Plichta, J.K. (2022) The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions. Annals of Surgical Oncology, 29, 6484-6494.
https://doi.org/10.1245/s10434-022-12313-6
|
[12]
|
Risom, T., Glass, D.R., Averbukh, I., Liu, C.C., Baranski, A., Kagel, A., Mccaffrey, E.F., Greenwald, N.F., Rivero-Gutiérrez, B., Strand, S.H., Varma, S., Kong, A., Keren, L., Sri-vastava, S., Zhu, C., Khair, Z., Veis, D.J., Deschryver, K., Vennam, S., Maley, C., Hwang, E.S., Marks, J.R., Bendall, S.C., Colditz, G.A., West, R.B. and Angelo, M. (2022) Transition to Invasive Breast Cancer Is Associated with Progres-sive Changes in the Structure and Composition of Tumor Stroma. Cell, 185, 299-310. https://doi.org/10.1016/j.cell.2021.12.023
|
[13]
|
Pleasant, V. (2022) Management of Breast Complaints and High-Risk Lesions. Best Practice & Research Clinical Obstetrics & Gynaecology, 83, 46-59. https://doi.org/10.1016/j.bpobgyn.2022.03.017
|
[14]
|
Zachariah, N.N., Basu, A., Gautam, N., Ramamoorthi, G., Kodumudi, K.N., Kumar, N.B., Loftus, L. and Czerniecki, B.J. (2021) Intercepting Premalignant, Preinvasive Breast Le-sions Through Vaccination. Frontiers in Immunology, 12, Article 786286. https://doi.org/10.3389/fimmu.2021.786286
|
[15]
|
Waaijer, L., Filipe, M.D., Simons, J., van der Pol, C.C., de Boorder, T., van Diest, P.J. and Witkamp, A.J. (2021) Detection of Breast Cancer Precursor Lesions by Autofluores-cence Ductoscopy. Breast Cancer, 28, 119-129.
https://doi.org/10.1007/s12282-020-01136-6
|
[16]
|
李羽禾, 何玥, 杨淑丽, 耿宇宁, 赵辉, 吴玉梅. 乳腺癌术后服用他莫昔芬对子宫内膜的影响研究[J]. 中国实用妇科与产科杂志, 2019, 35(8): 900-904.
|
[17]
|
Chen, J.Y., Kuo, S.J., Liaw, Y.P., Avital, I., Stojadinovic, A., Man, Y.G., Mannion, C., Wang, J., Chou, M.C., Tsai, H.D., Chen, S.T. and Hsiao, Y.H. (2014) Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Ta-moxifen Use: A Population Based Study. Journal of Cancer, 5, 151-155.
https://doi.org/10.7150/jca.8412
|
[18]
|
Keshavarz-Fathi, M. and Rezaei, N. (2021) Cancer Immunoprevention: Cur-rent Status and Future Directions. Archivum Immunologiae et Therapiae Experimentalis, 69, Article No. 3. https://doi.org/10.1007/s00005-021-00604-x
|
[19]
|
谭慧红, 范洪桥, 周亮, 刘丽芳. 从“伏毒-痰瘀-正虚”理论刍议“治未病”思想在乳腺癌癌前病变中的应用[J]. 中外医学研究, 2021, 19(10): 194-196.
|
[20]
|
孟博博, 芮苒, 尹诺男, 董夏, 方艳, 潘艳芳, 应小平. 中医药治疗乳腺癌癌前病变的Meta分析[J]. 中医学报, 2020, 35(2): 433-440.
|
[21]
|
李德辉, 苏伊璠, 范焕芳, 孙春霞, 韩长辉, 马盼, 闫娇娇, 吕素君. 西黄丸对大鼠乳腺癌癌前病变的阻断作用及对NF-κB蛋白表达的影响[J]. 中国老年学杂志, 2021, 41(1): 131-134.
|
[22]
|
张咏佳, 黄潘雯, 张永太, 王志, 冯年平. 西黄丸干预大鼠乳腺癌癌前病变的效果及机制研究[J/OL]. 中国中药杂志, 2023: 1-13.
https://kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C45S0n9fL2suRadTyEVl2pW9UrhTDCdPD676LcpQMGTrFWue4PWlvWMo3Sm8pv1yiN4Wxg5Lir-ers37T86A-NrZ&uniplatform=NZKPT&src=copy, 2023-06-29.
|
[23]
|
王志, 谢建絮, 李婉斯, 葛泓钰, 张永太, 冯年平. 麝香及西黄方中麝香酮在正常、乳腺癌癌前病变大鼠体内药动学的比较[J]. 中成药, 2020, 42(10): 2545-2550.
|
[24]
|
Bie, F., Zhang, G., Yan, X., Ma, X., Zhan, S., Qiu, Y., Cao, J., Ma, Y. and Ma, M. (2022) β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Gly-colysis Inhibition and AMPK Pathway Activation. Frontiers in Oncology, 12, Article 896904. https://doi.org/10.3389/fonc.2022.896904
|
[25]
|
谢建絮, 张咏佳, 黄潘雯, 张永太, 王志, 冯年平. 西黄方主要活性成分在乳腺癌癌前病变大鼠体内血浆药动学及尿排泄比较研究[J]. 中国中药杂志, 2023, 48(6): 1642-1651.
|
[26]
|
Liu, X.F., Li, J.W., Chen, H.Z., Sun, Z.Y., Shi, G.X., Zhu, J.M., Song, A.L., Wang, Y. and Li, X.Q. (2019) Yanghe Huayan Decoction Inhibits the Capability of Trans-Endothelium and Angiogenesis of HER2+ Breast Cancer via pAkt Signaling. Bioscience Reports, 39. https://doi.org/10.1042/BSR20181260
|
[27]
|
王云龙, 陈芬, 王芳. 阳和化岩汤干预乳腺癌癌前病变的效果及机制研究[J]. 中华中医药学刊, 2021, 39(3): 44-47+260.
|
[28]
|
王晓娜, 刘晓菲, 孙颖, 李斐斐, 史文娴. 阳和化岩汤对乳腺癌癌前病变细胞P53、Ki67表达的影响研究[J]. 中医药学报, 2020, 48(6): 9-13.
|
[29]
|
史文娴, 刘晓菲, 李斐斐, 王晓娜, 孙颖. 阳和化岩汤对乳腺癌癌前病变细胞凋亡关键因子Bcl-2、细胞色素C表达影响的机制研究[J]. 陕西中医, 2020, 41(6): 711-714+719.
|
[30]
|
孙颖, 刘晓菲, 王晓娜, 李斐斐, 史文娴, 郭光鑫. 阳和化岩汤对乳腺癌癌前病变细胞Fas、Caspase-3和Caspase-8表达的影响[J]. 现代中西医结合杂志, 2020, 29(17): 1825-1829.
|
[31]
|
Zhang, G., Jiang, X., Liu, Y., Hao, X., Wang, Y., Yan, X., Yu-an, N., Ma, Y. and Ma, M. (2019) Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precan-cerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation. Evidence-Based Complementary and Alternative Medicine, 2019, Article ID: 2795010. https://doi.org/10.1155/2019/2795010
|
[32]
|
Zhao, J., Pang, T., Jiao, J.P., Wang, B., Liu, X., Xiu, L.J., Sun, D.Z., Yue, X.Q. and Yu, C.Q. (2020) Xiaotan Jieyu Prescription Alleviates Breast Precancerous Lesions through PI3K/Akt Signaling Pathway. Evidence-Based Complementary and Alternative Medicine, 2020, Article ID: 4129461. https://doi.org/10.1155/2020/4129461
|
[33]
|
邓卫芳, 贾颖, 裴晓华. 逍遥丸对乳腺癌癌前病变大鼠乳腺组织CXCR4及VEGF表达的影响[J]. 中华中医药杂志, 2019, 34(4): 1386-1390.
|
[34]
|
李琳霈. 基于ER及PI3K/Akt/mTOR通路探讨疏肝健脾解毒方防治乳腺癌癌前病变的分子机制[D]: [博士学位论文]. 长沙: 湖南中医药大学, 2022.
|
[35]
|
李琳霈, 杨晓, 王容容, 潘博, 蒋益兰, 柏正平. 疏肝健脾解毒方对乳腺癌癌前病变肝郁证大鼠模型乳腺组织血管生成的影响[J]. 湖南中医药大学学报, 2019, 39(10): 1195-1199.
|
[36]
|
万杰鑫, 赵斌, 胡慧明, 吴双双, 官扬. 基于网络药理学分析疏肝健脾解毒方抗乳腺癌潜在靶点和作用机制[J]. 江西中医药, 2021, 52(11): 61-69.
|
[37]
|
张朴, 王梦静, 裴慧, 刘小春, 武珊, 赵娴. 针刺调控下丘脑-垂体-性腺轴防治乳腺癌癌前病变的选穴思路探讨[J]. 山东中医杂志, 2022, 41(8): 875-879.
|